WallSt.net Announces Upcoming Interview with CEO of BioSante Pharmaceuticals
September 24 2007 - 1:57PM
PR Newswire (US)
NEW YORK, Sept. 24 /PRNewswire/ -- Stephen Simes, chief executive
officer of BioSante Pharmaceuticals, Inc. (AMEX:BPA)
(http://www.biosantepharma.com/) will be featured in an exclusive
interview with http://www.wallst.net/ scheduled for September 26 at
10:30 a.m. EDT. The interview will be posted on
http://www.wallst.net/ by 8 p.m. EDT on September 26. The interview
will cover topics including BioSante's market potential, growth
initiatives, competitive edge, recent news, and milestones for
which investors should watch. To hear the interview in its
entirety, visit http://www.wallst.net/, and click on "Interviews."
The interview can be accessed either by locating the company's
ticker symbol under the appropriate exchange at the top of the
"Interviews" section or by entering the company's ticker symbol in
the Search Archive window on the right-hand column of the
"Interviews" section once it is posted. About BioSante
Pharmaceuticals, Inc. BioSante is developing a pipeline of hormone
therapy products to treat both men and women. These hormone therapy
products are gel formulations for transdermal administration that
deliver bioidentical estradiol and testosterone. BioSante's lead
products include Elestrin(TM) (estradiol gel) developed through FDA
approval by BioSante indicated for the treatment of
moderate-to-severe vasomotor symptoms associated with menopause,
and LibiGel(R) (transdermal testosterone gel) in Phase III clinical
development by BioSante for the treatment of female sexual
dysfunction (FSD). Also in development is Bio-T-Gel(TM), a
testosterone gel for male hypogonadism, and an oral contraceptive
in Phase II clinical development using BioSante patented
technology. The current market in the U.S. for estrogen and
testosterone products is approximately $2.5 billion and for oral
contraceptives approximately $3.0 billion. The company also is
developing its calcium phosphate nanotechnology (CaP) for novel
vaccines, including hepatitis B, avian flu and biodefense vaccines
for toxins such as anthrax, as well as a system for delivering
drugs via alternative routes of administration and for aesthetic
medicine. Additional information is available online at
http://www.biosantepharma.com/. About WallSt.net:
http://www.wallst.net/ is owned and operated by WallStreet Direct,
Inc., a wholly owned subsidiary of Financial Media Group, Inc. The
Website is a leading provider of timely business news, executive
interviews, multimedia content, and research tools. Financial Media
Group, Inc. also owns http://www.mywallst.net/, a financial social
network for investors, Financial Filings Corp., a provider of
compliance solutions to publicly traded companies, and WallStRadio,
a business and finance podcast Website. Financial Filings Corp. is
expecting to receive two hundred eighty dollars from BioSante
Pharmaceuticals, Inc. for the dissemination of this press release.
For a complete list of our advertisers and advertising
relationships, visit
http://www.wallst.net/disclaimer/disclaimer.asp. (Logo:
http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO) Contact:
WallSt.net 800-4-WALL-ST
http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO
http://photoarchive.ap.org/ DATASOURCE: Financial Filings Corp.
CONTACT: WallSt.net, 1-800-4-WALL-ST Web site:
http://www.financialfilings.com/ http://www.biosantepharma.com/
Copyright
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Jul 2023 to Jul 2024